Variables | No./meanāĀ±āSD | Univariate cox analysis | Multivariate cox analysis | Multivariate logistic analysis | ||||||
---|---|---|---|---|---|---|---|---|---|---|
HR | 95%CI | P-value | HR | 95%CI | P-value | OR | 95%CI | P-value | ||
Gender | ||||||||||
Ā Male | 237 (82.87%) | reference | Ā | Ā | Ā | Ā | Ā | Ā | Ā | Ā |
Ā Female | 49 (17.13%) | 0.87 | 0.56ā1.34 | 0.519 | Ā | Ā | Ā | Ā | Ā | Ā |
Age (years) | ||||||||||
Ā ā¤ā60 | 199 (69.58%) | reference | Ā | Ā | Ā | Ā | Ā | Ā | Ā | Ā |
Ā >ā60 | 87 (30.42%) | 0.89 | 0.63ā1.24 | 0.479 | Ā | Ā | Ā | Ā | Ā | Ā |
Hypertension | ||||||||||
Ā Without | 212 (74.13%) | reference | Ā | Ā | Ā | Ā | Ā | Ā | Ā | Ā |
Ā With | 74 (25.87%) | 1.23 | 0.88ā1.73 | 0.2305 | Ā | Ā | Ā | Ā | Ā | Ā |
Diabetes | ||||||||||
Ā Without | 240 (83.92%) | reference | Ā | Ā | Ā | Ā | Ā | Ā | Ā | Ā |
Ā With | 46 (16.08%) | 0.96 | 0.63ā1.46 | 0.8547 | Ā | Ā | Ā | Ā | Ā | Ā |
Coronary heart disease | ||||||||||
Ā Without | 275 (96.15%) | reference | Ā | Ā | Ā | Ā | Ā | Ā | Ā | Ā |
Ā With | 11 (3.85%) | 1.15 | 0.54ā2.46 | 0.7171 | Ā | Ā | Ā | Ā | Ā | Ā |
Smoking history | ||||||||||
Ā Without | 161 (56.29%) | reference | Ā | Ā | Ā | Ā | Ā | Ā | Ā | Ā |
Ā With | 125 (43.71%) | 1.05 | 0.77ā1.43 | 0.7508 | Ā | Ā | Ā | Ā | Ā | Ā |
Drinking history | ||||||||||
Ā Without | 198 (69.23%) | reference | Ā | Ā | Ā | Ā | Ā | Ā | Ā | Ā |
Ā With | 88 (30.77%) | 0.96 | 0.69ā1.33 | 0.802 | Ā | Ā | Ā | Ā | Ā | Ā |
Portal hypertension | ||||||||||
Ā Without | 221 (77.27%) | reference | Ā | Ā | Ā | Ā | Ā | Ā | Ā | Ā |
Ā With | 65 (22.73%) | 1.27 | 0.89ā1.81 | 0.1855 | Ā | Ā | Ā | Ā | Ā | Ā |
Preoperative Ln AFP level | 4.62āĀ±ā2.95 | 1.07 | 1.02ā1.13 | 0.0081 | 1.05 | 1.00ā1.11 | 0.063 | 1.12 | 1.02- 1.23 | 0.0147 |
ALBI score | ||||||||||
Ā ā¤āā 2.60 | 256 (89.51%) | reference | Ā | Ā | reference | Ā | Ā | Ā | Ā | Ā |
Ā >āā 2.60 toāā¤āā 1.39 | 30 (10.49%) | 2.15 | 1.41ā3.27 | 0.0004 | 1.94 | 1.10ā3.43 | 0.0218 | 2.04 | 0.86- 4.82 | 0.1056 |
Preoperative PT (second) | 11.92āĀ±ā0.95 | 1.12 | 0.95ā1.32 | 0.1671 | Ā | Ā | Ā | Ā | Ā | Ā |
Preoperative blood glucose level (mmol/L) | 5.62āĀ±ā1.72 | 1.05 | 0.96ā1.16 | 0.276 | Ā | Ā | Ā | Ā | Ā | Ā |
Preoperative serum creatinine level (mg/dl) | 73.35āĀ±ā14.29 | 0.99 | 0.98ā1.00 | 0.1635 | Ā | Ā | Ā | Ā | Ā | Ā |
Preoperative ALB (g/L) | 44.02āĀ±ā4.19 | 0.95 | 0.91ā0.98 | 0.004 | 1.01 | 0.96ā1.05 | 0.8346 | Ā | Ā | Ā |
Preoperative ALT (U/L) | 35.16āĀ±ā23.38 | 1 | 1.00- 1.01 | 0.2086 | Ā | Ā | Ā | Ā | Ā | Ā |
Preoperative AST (U/L) | 34.68āĀ±ā22.96 | 1.01 | 1.00- 1.01 | 0.006 | 1 | 1.00ā1.01 | 0.5784 | Ā | Ā | Ā |
Preoperative HBsAg | ||||||||||
Ā Positive | 232 (81.12%) | reference | Ā | Ā | Ā | Ā | Ā | Ā | Ā | Ā |
Ā Negative | 54 (18.88%) | 1.08 | 0.74ā1.58 | 0.692 | Ā | Ā | Ā | Ā | Ā | Ā |
Preoperative HBeAg | ||||||||||
Ā Negative | 221 (77.27%) | reference | Ā | Ā | reference | Ā | Ā | Ā | Ā | Ā |
Ā Positive | 65 (22.73%) | 1.43 | 1.01ā2.02 | 0.0454 | 1.52 | 1.04ā2.20 | 0.0286 | 1.93 | 1.02- 3.65 | 0.0427 |
HCV-Ab | ||||||||||
Ā Negative | 266 (93.01%) | reference | Ā | Ā | Ā | Ā | Ā | Ā | Ā | Ā |
Ā Positive | 20 (6.99%) | 1.17 | 0.67ā2.07 | 0.5795 | Ā | Ā | Ā | Ā | Ā | Ā |
AdjacentĀ to large blood vessels | ||||||||||
Ā Without | 196 (68.53%) | reference | Ā | Ā | Ā | Ā | Ā | Ā | Ā | Ā |
Ā With | 90 (31.47%) | 1.17 | 0.84ā1.61 | 0.3517 | Ā | Ā | Ā | Ā | Ā | Ā |
AdjacentĀ to the diaphragm | ||||||||||
Ā Without | 262 (91.61%) | reference | Ā | Ā | Ā | Ā | Ā | Ā | Ā | Ā |
Ā With | 24 (8.39%) | 2.14 | 1.34ā3.42 | 0.0014 | 1.24 | 0.74ā2.09 | 0.4138 | Ā | Ā | Ā |
MVI classification | ||||||||||
Ā M1 | 132 (46.15%) | reference | Ā | Ā | reference | Ā | Ā | reference | Ā | Ā |
Ā M2 | 66 (23.08%) | 2.7 | 1.83ā3.99 | ā<ā0.0001 | 2.14 | 1.41ā3.25 | 0.0004 | 2.3 | 1.17- 4.52 | 0.0157 |
Ā MX | 88 (30.77%) | 1.7 | 1.17ā2.47 | 0.0054 | 1.29 | 0.86ā1.93 | 0.21 | 1.65 | 0.88- 3.12 | 0.1202 |
Largest tumor diameter (cm) | ||||||||||
Ā ā¤ā5 | 170 (59.44%) | reference | Ā | Ā | reference | Ā | Ā | Ā | Ā | Ā |
Ā >ā5 | 116 (40.56%) | 1.99 | 1.46ā2.71 | ā<ā0.0001 | 1.56 | 1.10ā2.22 | 0.0124 | 1.78 | 1.01- 3.14 | 0.0476 |
Number of tumors | ||||||||||
Ā 1 | 250 (87.41%) | reference | Ā | Ā | reference | Ā | Ā | reference | Ā | Ā |
Ā ā„ā2 | 36 (12.59%) | 1.77 | 1.17ā2.66 | 0.0064 | 1.66 | 1.08ā2.55 | 0.0209 | 2.06 | 0.93- 4.56 | 0.0755 |
Satellite nodule | ||||||||||
Ā Without | 237 (82.87%) | reference | Ā | reference | Ā | Ā | Ā | reference | Ā | Ā |
Ā With | 49 (17.13%) | 1.79 | 1.23ā2.59 | 0.0022 | 1.44 | 0.97ā2.14 | 0.0726 | 1.95 | 0.97- 3.91 | 0.0606 |
Serosal invasion | ||||||||||
Ā Without | 114 (39.86%) | reference | Ā | reference | Ā | Ā | Ā | reference | Ā | Ā |
Ā With | 172 (60.14%) | 1.97 | 1.41ā2.76 | ā<ā0.0001 | 1.59 | 1.11ā2.28 | 0.0109 | 2.06 | 1.17- 3.64 | 0.0129 |
Preoperative/intraoperative ablation | ||||||||||
Ā Without | 279 (97.55%) | reference | Ā | Ā | Ā | Ā | Ā | Ā | Ā | Ā |
Ā With | 7 (2.45%) | 1.07 | 0.34ā3.35 | 0.9105 | Ā | Ā | Ā | Ā | Ā | Ā |
Preoperative radiotherapy | ||||||||||
Ā Without | 280 (97.90%) | reference | Ā | Ā | Ā | Ā | Ā | Ā | Ā | Ā |
Ā With | 6 (2.10%) | 1.08 | 0.34ā3.38 | 0.9000 | Ā | Ā | Ā | Ā | Ā | Ā |
Preoperative interventional therapy | ||||||||||
Ā Without | 270 (94.41%) | reference | Ā | Ā | Ā | Ā | Ā | Ā | Ā | Ā |
Ā With | 16 (5.59%) | 1.56 | 0.85ā2.88 | 0.1536 | Ā | Ā | Ā | Ā | Ā | Ā |
Postoperative radiotherapy | ||||||||||
Ā Without | 239 (83.57%) | reference | Ā | Ā | Ā | Ā | Ā | Ā | Ā | Ā |
Ā With | 47 (16.43%) | 0.89 | 0.59ā1.35 | 0.5919 | Ā | Ā | Ā | Ā | Ā | Ā |
Postoperative interventional therapy | ||||||||||
Ā Without | 172 (60.14%) | reference | Ā | Ā | Ā | Ā | Ā | Ā | Ā | Ā |
Ā With | 114 (39.86%) | 1.23 | 0.90ā1.67 | 0.1919 | Ā | Ā | Ā | Ā | Ā | Ā |